Effect of interleukin-2 on long term infusion treatment regimen of ch14.18/CHO antibody on activity in relapsed/refractory neuroblastoma patients.

被引：0
|
作者：
Loibner, Hans
Siebert, Nikolai
Eger, Christin
Janzek, Evelyne
Ladenstein, Ruth
Lode, Holger N.
机构：
[1] Apeiron Biol AG, Vienna, Austria
[2] Univ Med Greifswald, Greifswald, Germany
[3] Apeiron Biol, Vienna, Austria
[4] St Anna Childrens Hosp & Res Inst, Paediat Haematol Oncol, SIOP Europe Neuroblastoma Grp, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10563
引用
收藏
页数：2
相关论文
共 47 条
  • [1] INTERLEUKIN-2 ADDS TOXICITY BUT NO MEASURABLE ACTIVITY IN RELAPSED/REFRACTORY NEUROBLASTOMA PATIENTS TREATED WITH LONG-TERM INFUSION OF ANTI GD2 ANTIBODY CH14.18/CHO
    Lode, H.
    Siebert, N.
    Eger, C.
    Schuster, M.
    Janzek, E.
    Loibner, H.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S224 - S224
  • [2] Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Loibner, Hans
    Mueller, Ina
    Ladenstein, Ruth L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Immunomodulation following treatment with ch14.18 and interleukin 2 in patients with refractory neuroblastoma
    Brackrock, D.
    Siebert, N.
    Lode, H. N.
    KLINISCHE PADIATRIE, 2011, 223 (03): : 200 - 200
  • [4] RELAPSED/REFRACTORY NEUROBLASTOMA PATIENTS RESPOND TO ANTI GD2 ANTIBODY CH14.18/CHO DELIVERED BY LONG-TERM INFUSION COMBINED WITH INTERLEUKIN-2 AND SHOW IMPROVED SURVIVAL RATES COMPARED TO HISTORICAL CONTROLS
    Lode, H.
    Valteau-Couanet, D.
    Manzitti, C.
    Gray, J.
    Castel, V.
    Yaniv, I.
    Siebert, N.
    Jensen, C.
    Endres, S.
    Pill, L.
    Eger, C.
    Seidel, D.
    Juettner, M.
    Kietz, S.
    Ehlert, K.
    Janzek, E.
    Loibner, H.
    Mueller, I.
    Ladenstein, R.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S224 - S225
  • [5] Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma
    Ceylan, Kiraz
    Jahns, Luciana J.
    Lode, Bjoern N.
    Ehlert, Karoline
    Kietz, Silke
    Troschke-Meurer, Sascha
    Siebert, Nikolai
    Lode, Holger N.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (06)
  • [6] Immune activation and clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients.
    Lode, Holger N.
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Siebert, Nikolai
    Kietz, Silke
    Ehlert, Karoline
    Brock, Penelope
    Valteau-Couanet, Dominique
    Janzek, Evelyne
    Loibner, Hans
    Ladenstein, Ruth L.
    Mueller, Ina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
    Siebert, Nikolai
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Zumpe, Maxi
    Wegner, Danilo
    Kietz, Silke
    Ehlert, Karoline
    Veal, Gareth J.
    Siegmund, Werner
    Weiss, Michael
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    MABS, 2016, 8 (03) : 604 - 616
  • [8] Phase I bridging study of ch14.18/CHO long-term infusion in recurrent or refractory neuroblastoma patients in Japan.
    Takahashi, Yoshiyuki
    Narita, Atsushi
    Siebert, Nikolai
    Nishio, Nobuhiro
    Xu, Yinyan
    Muramatsu, Hideki
    Hama, Asahito
    Kamijo, Takehiko
    Nakazawa, Atsuko
    Hosoi, Hajime
    Kinoshita, Yoshiaki
    Shimizu, Shinobu
    Kato, Katsuyoshi
    Mizuno, Masaaki
    Loibner, Hans
    Tajiri, Tatsuro
    Nakagawara, Akira
    Ladenstein, Ruth
    Lode, Holger N.
    Kojima, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients A SIOPEN phase 1 study
    Ladenstein, Ruth
    Weixler, Silke
    Baykan, Bianca
    Bleeke, Matthias
    Kunert, Renate
    Katinger, Dietmar
    Pribill, Ingrid
    Glander, Petra
    Bauer, Steffen
    Pistoia, Vito
    Michon, Jean
    Garaventa, Alberto
    Lode, Holger N.
    MABS, 2013, 5 (05) : 801 - 809
  • [10] Immune activation, clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients
    Lode, Holger
    Jensen, Christian
    Siebert, Nikolai
    Kietz, Silke
    Ehlert, Karoline
    Mueller, Ina
    Ladenstein, Ruth
    Janzek, Evelyne
    Loibner, Hans
    CANCER RESEARCH, 2014, 74 (19)
12345